V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 220020952 | 220009142 | 1.62 | 78.4 | null | 2017-12-13 | 2017-12-13 | IPO | N | N | 220034434 | CYCLOPHOSPHAMIDE HIGH DOSE |
| 220020953 | 220009154 | null | 35.8 | Curative (C) | 2017-05-29 | 2017-08-04 | NHL 2003 Gp C M1 | N | N | 220034482 | PEMBROLIZUMAB |
| 220020954 | 220009161 | null | 67.5 | Curative (C) | 2015-02-11 | 2015-02-25 | Cytarabine+Methotrexate Intrathecal | N | N | 220034495 | METHOTREXATE + PEGASPARGASE |
| 220020955 | 220009169 | 1.71 | 44.8 | null | 2019-09-28 | 2019-09-28 | Arsenic Triox + Tretinoin Ind W1-4 | N | N | 220034510 | VINORELBINE |
| 220020956 | 220009185 | 1.72 | 66.5 | Palliative (P) | 2016-07-12 | 2016-07-12 | ALL UKALL60+ TRIAL | 2 | N | 220034571 | CLOFARABINE + DAUNORUBICIN |
| 220020957 | 220009195 | 1.6 | 44.4 | Curative (C) | 2016-07-19 | 2016-07-20 | AML LI-1 Trial | 2 | N | 220034611 | MACE |
| 220020958 | 220014898 | 1.59 | 20.9 | Curative (C) | 2018-08-23 | 2018-08-23 | Pemetrexed | 02 | N | 220034662 | CETUXIMAB |
| 220020959 | 220009207 | 1.61 | 64.6 | Curative (C) | 2014-01-06 | 2014-03-29 | CISPLATIN + ETOPOSIDE | 1 | N | 220034670 | BUSULFAN + CYCLOPHOSPHAMIDE |
| 220020960 | 220009214 | null | null | Curative (C) | 2017-02-27 | 2017-10-27 | ETOPOSIDE | null | N | 220034678 | CISPLATIN + FLUOROURACIL |
| 220020961 | 220009219 | 1.69 | 79.9 | Curative (C) | 2016-08-26 | 2016-09-15 | BENDAMUSTINE + RITUXIMAB | 01 | null | 220034690 | PERTUZUMAB + TRASTUZUMAB |
| 220020962 | 220009224 | 1.76 | 66.5 | Curative (C) | 2013-07-13 | 2014-01-27 | CETUXIMAB | 2 | N | 220034697 | ARSENIC TRIOXIDE + ATRA |
| 220020963 | 220009240 | 1.5 | 115.4 | Curative (C) | 2014-12-13 | 2014-12-25 | CYTARABINE + FLUDARABINE | N | N | 220034796 | MA |
| 220020964 | 220009250 | 0 | 87 | Curative (C) | 2016-03-05 | 2016-03-05 | ALL UKALL60+ TRIAL | 02 | N | 220034834 | INTERFERON |
| 220020965 | 220018143 | null | 75 | Curative (C) | 2017-05-16 | 2017-05-16 | FIGARO TRIAL | null | null | 220034845 | UKALL60+ |
| 220020966 | 220009266 | 1.64 | 62.7 | Curative (C) | 2015-08-01 | 2015-08-02 | Alemtuzumab + Cyclophos TBI Allo | N | Y | 220034935 | UKALL2011 |
| 220020967 | 220009279 | 1.3 | 45 | Disease modification (D) | 2016-12-27 | 2017-01-04 | Bevacizumab+Carbo+Pacliaxel | N | null | 220035065 | BUSULFAN + FLUDARABINE |
| 220020970 | 220021011 | 1.64 | 88.65 | Palliative (P) | 2015-03-11 | 2015-04-14 | Ifosfamide | N | N | 220035113 | DABRAFENIB + TRAMETINIB |
| 220020971 | 220009302 | 1.72 | 53 | Curative (C) | 2016-12-23 | 2017-07-14 | GCLAC | 2 | N | 220035146 | UKALL 2003 |
| 220020972 | 220009314 | 1.72 | 72.3 | Curative (C) | 2018-07-01 | 2018-07-07 | CETUXIMAB | N | null | 220035189 | BORTEZOMIB + THALIDOMIDE |
| 220020973 | 220009326 | 1.95 | 111 | Disease modification (D) | 2019-03-17 | 2019-03-23 | Doxorubin 50mg/m2 | 02 | N | 220035229 | BUSULPHAN |
| 220020974 | 220018160 | 1.58 | 62.899 | Curative (C) | 2017-12-27 | 2018-01-15 | ALEMTUZUMAB + BUSULFAN + CYCLOPHOSPHAMIDE + MELPHALAN | null | null | 220035232 | METHOTREXATE + PEGASPARGASE |
| 220020975 | 220009341 | 1.64 | 53 | Curative (C) | 2015-04-08 | 2015-05-01 | FIGARO TRIAL | N | N | 220035299 | ARSENIC TRIOXIDE + ATRA |
| 220020976 | 220009346 | 1.72 | 83.7 | null | 2015-04-19 | 2015-04-19 | Cetuximab + FOLFIRI cycle 2 onwards | N | N | 220035329 | ALEMTUZUMAB + CYCLO + FLUDARABINE |
| 220020977 | 220009348 | null | 83.2 | Disease modification (D) | 2014-02-09 | 2014-02-09 | ATG + Busulfan + Fludarabine + Thiotepa | N | N | 220035332 | CYTARABINE + FLUDARABINE + IDARUBICIN |
| 220020978 | 220009352 | 1.54 | 64 | Palliative (P) | 2013-05-11 | 2013-05-12 | INTERFERON | N | N | 220035347 | CETUXIMAB + CISPLATIN + FU |
| 220020979 | 220009360 | null | 77 | Curative (C) | 2018-03-27 | 2018-03-27 | Gemcitabine weekly | N | N | 220035373 | PEMBROLIZUMAB |
| 220020980 | 220009364 | 1.7 | null | Curative (C) | 2018-01-13 | 2018-01-16 | FLUDARABINE | null | null | 220035392 | CYTARABINE IT + METHOTREXATE |
| 220020981 | 220009368 | 1.7 | 61.9 | Disease modification (D) | 2017-07-05 | 2017-07-11 | VINORELBINE | 02 | null | 220035406 | VIOLA TRIAL |
| 220020982 | 220009372 | null | 103.75 | Palliative (P) | 2016-04-14 | 2016-04-15 | ALEMTUZUMAB + BUSULFAN + CYCLOPHOSPHAMIDE + MELPHALAN | N | N | 220035412 | BEP |
| 220020983 | 220009378 | 1.9 | 0 | Curative (C) | 2014-04-21 | 2014-04-22 | PEMBROLIZUMAB | N | N | 220035414 | MA |
| 220020984 | 220009381 | 1.68 | null | Curative (C) | 2019-01-03 | 2019-02-13 | Bevacizumab 5mg/kg | 02 | N | 220035428 | GEMCITABINE |
| 220020986 | 220009393 | 1.81 | 80.3 | Curative (C) | 2014-05-16 | 2014-06-27 | FIGARO TRIAL | 02 | N | 220035488 | CAPECITABINE + OXALIPLATIN |
| 220020987 | 220009398 | 1.75 | 65 | Curative (C) | 2014-04-21 | 2014-05-08 | ALEMTUZUMAB + FLUDARABINE | 2 | N | 220035497 | QUASAR 2 TRIAL |
| 220020988 | 220009401 | null | null | null | 2017-01-06 | 2017-01-06 | Spanish Maintenance (Months 4-24) | null | N | 220035535 | CLOFARABINE + DAUNORUBICIN |
| 220020990 | 220018180 | null | 17.1 | Curative (C) | 2015-05-27 | 2015-07-06 | Etoposide oral | 02 | N | 220035549 | BENDAMUSTINE + RITUXIMAB |
| 220020991 | 220009413 | null | 67 | Palliative (P) | 2018-01-06 | 2018-01-10 | NHL 2003 Gp C M1 | N | null | 220035566 | CYTARABINE IT + METHOTREXATE |
| 220020992 | 220009424 | null | null | Palliative (P) | 2014-08-29 | 2014-08-29 | PAD | N | N | 220035632 | EOX |
| 220020993 | 220009427 | 0 | 50.3 | Curative (C) | 2016-05-06 | 2016-08-15 | BUSULFAN + FLUDARABINE + METHOTREXATE | 02 | N | 220035638 | TRASTUZUMAB |
| 220020994 | 220015002 | 1.62 | 76 | Disease modification (D) | 2015-08-09 | 2015-08-09 | MidAC | N | N | 220035672 | MACE |
| 220020995 | 220009439 | null | 86 | Curative (C) | 2017-10-11 | 2017-10-11 | ALEMTUZUMAB + BUSULFAN + CYCLOPHOSPHAMIDE + MELPHALAN | Y | null | 220035742 | ARSENIC TRIOXIDE |
| 220020997 | 220015008 | 1.49 | 58.8 | Disease modification (D) | 2018-05-11 | 2018-05-19 | ALEMTUZUMAB + FLUDARABINE | 02 | N | 220035765 | ROMAZA TRIAL |
| 220020998 | 220015024 | 1.82 | 23.7 | null | 2014-12-03 | 2015-01-11 | Venetoclax | 02 | N | 220035925 | CYTARABINE + FLUDARABINE + IDARUBICIN |
| 220020999 | 220018197 | 1.62 | 102.4 | Adjuvant (A) | null | 2014-03-25 | Mercaptopurine | 02 | N | 220035943 | INTERFERON |
| 220021000 | 220009475 | null | 66.95 | Curative (C) | 2017-08-06 | 2017-08-09 | Cetuximab 7 day (>Cycle 2) | N | N | 220035947 | BORTEZOMIB |
| 220021001 | 220009489 | null | null | null | 2014-07-20 | 2014-07-22 | BENDAMUSTINE + RITUXIMAB | N | null | 220036013 | PEMBROLIZUMAB |
| 220021002 | 220015036 | 1.69 | 61.7 | Curative (C) | 2015-03-17 | 2015-03-17 | Bevacizumab 5mg/kg | 2 | N | 220036034 | EVEROLIMUS |
| 220021003 | 220009498 | 1.63 | 87.2 | Curative (C) | 2017-01-21 | 2017-01-24 | Etoposide oral | 2 | N | 220036060 | CAPECITABINE + CARBOPLATIN |
| 220021004 | 220009500 | null | 11.4 | Curative (C) | 2015-12-28 | 2016-03-16 | FIGARO TRIAL | 02 | N | 220036062 | BUSULPHAN + CYCLO |
| 220021005 | 220009510 | 1.8 | null | Curative (C) | 2015-12-01 | 2015-12-03 | ALL UKALL60+ TRIAL | N | N | 220036121 | LIPOSOMAL CYTARABINE |
| 220021007 | 220009527 | 1.77 | 84.5 | Palliative (P) | null | 2016-03-24 | TRASTUZUMAB | N | N | 220036202 | IPILIMUMAB |